Grow Group’s Pharma Pierre van Weperen talks to Proactive London about his experience in the cannabis medicines industry and extended strategic relationship with Canadian firm Aurora Cannabis Inc (NYSE:ACB).
The two firms have signed a two-year market access services agreement for the UK, following an initial agreement in 2019.
Grow, which is focused on making cannabis-based medicines accessible to patients in the UK and Europe, also said it is currently raising £6mln of capital and will have some remaining allocation for sophisticated investors or high net worth investors.
Read More: Grow Group extend relationship with Aurora Cannabis as their ‘agent, distributor